At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 841 enrolled
Drug / intervention
Arformoterol +1 moredrug
Likely dose
Arformoterol 15 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 3 clinical trial evaluating Arformoterol and Placebo for Chronic Obstructive Pulmonary Disease. Completed, enrolled 841 participants across 73 sites.
Detailed Summary
This is a multi-center study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. Study participation will consist of a total of 6 visits over approximately 1 year.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJun 2009
Primary CompletionJun 2012
TodayJul 2026
First PostedMay 28, 2009
Enrollment StartJun 1, 2009
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 17.1 years ago
Interventions
Arformoteroldrug
Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
Placebodrug
Placebo inhalation solution, twice daily (BID) for a duration of one year.